Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy

The pharmacological treatment of mesial temporal lobe epilepsy (mTLE), the most common epileptic syndrome in adults, is still unsatisfactory, as one third of the patients are or become refractory to antiepileptic agents. Refractoriness may depend upon drug-induced alterations, but the disease per se...

Full description

Bibliographic Details
Main Authors: Pierangelo eCifelli, Eleonora ePalma, Cristina eRoseti, Gianluca eVerlengia, Michele eSimonato
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-07-01
Series:Frontiers in Cellular Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fncel.2013.00108/full
id doaj-0d22b88ab5774503aa480f4c6bd02469
record_format Article
spelling doaj-0d22b88ab5774503aa480f4c6bd024692020-11-24T23:31:18ZengFrontiers Media S.A.Frontiers in Cellular Neuroscience1662-51022013-07-01710.3389/fncel.2013.0010854360Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsyPierangelo eCifelli0Eleonora ePalma1Cristina eRoseti2Gianluca eVerlengia3Michele eSimonato4Ri.MED FoundationUniversity of Rome La SapienzaUniversity of Rome La SapienzaUniversity of FerraraUniversity of FerraraThe pharmacological treatment of mesial temporal lobe epilepsy (mTLE), the most common epileptic syndrome in adults, is still unsatisfactory, as one third of the patients are or become refractory to antiepileptic agents. Refractoriness may depend upon drug-induced alterations, but the disease per se may also undergo a progressive evolution that affects the sensitivity to drugs. mTLE has been shown to be associated with a dysfunction of the inhibitory signaling mediated by GABAA receptors. In particular, the repetitive activation of GABAA receptors produces a use-dependent decrease (rundown) of the evoked currents (IGABA), which is markedly enhanced in the hippocampus and cortex of drug-resistant mTLE patients. This phenomenon has been also observed in the pilocarpine model, where the increased IGABA rundown is observed in the hippocampus at the time of the first spontaneous seizure, then extends to the cortex and remains constant in the chronic phase of the disease. Here, we examined the sensitivity of IGABA to pharmacological modulation. We focused on the antiepileptic agent levetiracetam and on the neurotrophin BDNF, which were previously reported to attenuate mTLE-induced increased rundown in the chronic human tissue. In the pilocarpine model, BDNF displayed a paramount effect, decreasing rundown in the hippocampus at the time of the first seizure, as well as in the hippocampus and cortex in the chronic period. In contrast, levetiracetam did not affect rundown in the hippocampus, but attenuated it in the cortex. Interestingly, this effect of levetiracetam was also observed on the still unaltered rundown observed in the cortex at the time of the first spontaneous seizure. These data suggest that the sensitivity of GABAA receptors to pharmacological interventions undergoes changes during the natural history of mTLE, implicating that the site of seizure initiation and the timing of treatment may highly affect the therapeutic outcome.http://journal.frontiersin.org/Journal/10.3389/fncel.2013.00108/fullHippocampusNeocortexPilocarpineBDNFGABAlevetiracetam
collection DOAJ
language English
format Article
sources DOAJ
author Pierangelo eCifelli
Eleonora ePalma
Cristina eRoseti
Gianluca eVerlengia
Michele eSimonato
spellingShingle Pierangelo eCifelli
Eleonora ePalma
Cristina eRoseti
Gianluca eVerlengia
Michele eSimonato
Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy
Frontiers in Cellular Neuroscience
Hippocampus
Neocortex
Pilocarpine
BDNF
GABA
levetiracetam
author_facet Pierangelo eCifelli
Eleonora ePalma
Cristina eRoseti
Gianluca eVerlengia
Michele eSimonato
author_sort Pierangelo eCifelli
title Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy
title_short Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy
title_full Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy
title_fullStr Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy
title_full_unstemmed Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy
title_sort changes in the sensitivity of gabaa current rundown to drug treatments in a model of temporal lobe epilepsy
publisher Frontiers Media S.A.
series Frontiers in Cellular Neuroscience
issn 1662-5102
publishDate 2013-07-01
description The pharmacological treatment of mesial temporal lobe epilepsy (mTLE), the most common epileptic syndrome in adults, is still unsatisfactory, as one third of the patients are or become refractory to antiepileptic agents. Refractoriness may depend upon drug-induced alterations, but the disease per se may also undergo a progressive evolution that affects the sensitivity to drugs. mTLE has been shown to be associated with a dysfunction of the inhibitory signaling mediated by GABAA receptors. In particular, the repetitive activation of GABAA receptors produces a use-dependent decrease (rundown) of the evoked currents (IGABA), which is markedly enhanced in the hippocampus and cortex of drug-resistant mTLE patients. This phenomenon has been also observed in the pilocarpine model, where the increased IGABA rundown is observed in the hippocampus at the time of the first spontaneous seizure, then extends to the cortex and remains constant in the chronic phase of the disease. Here, we examined the sensitivity of IGABA to pharmacological modulation. We focused on the antiepileptic agent levetiracetam and on the neurotrophin BDNF, which were previously reported to attenuate mTLE-induced increased rundown in the chronic human tissue. In the pilocarpine model, BDNF displayed a paramount effect, decreasing rundown in the hippocampus at the time of the first seizure, as well as in the hippocampus and cortex in the chronic period. In contrast, levetiracetam did not affect rundown in the hippocampus, but attenuated it in the cortex. Interestingly, this effect of levetiracetam was also observed on the still unaltered rundown observed in the cortex at the time of the first spontaneous seizure. These data suggest that the sensitivity of GABAA receptors to pharmacological interventions undergoes changes during the natural history of mTLE, implicating that the site of seizure initiation and the timing of treatment may highly affect the therapeutic outcome.
topic Hippocampus
Neocortex
Pilocarpine
BDNF
GABA
levetiracetam
url http://journal.frontiersin.org/Journal/10.3389/fncel.2013.00108/full
work_keys_str_mv AT pierangeloecifelli changesinthesensitivityofgabaacurrentrundowntodrugtreatmentsinamodeloftemporallobeepilepsy
AT eleonoraepalma changesinthesensitivityofgabaacurrentrundowntodrugtreatmentsinamodeloftemporallobeepilepsy
AT cristinaeroseti changesinthesensitivityofgabaacurrentrundowntodrugtreatmentsinamodeloftemporallobeepilepsy
AT gianlucaeverlengia changesinthesensitivityofgabaacurrentrundowntodrugtreatmentsinamodeloftemporallobeepilepsy
AT micheleesimonato changesinthesensitivityofgabaacurrentrundowntodrugtreatmentsinamodeloftemporallobeepilepsy
_version_ 1725538514225856512